The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline.
Lyon, France, and Cambridge, MA, July 15, 2024 — Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed.